Jonathan Yu

Jonathan is the Chief Business Officer and oversees corporate strategy, business development and commercial strategy at Disc Medicine. Previously, he was a co-founder of Qpex Biopharma and the Vice President of Corporate Strategy, Finance and Operations, where he led all business functions including the spin-out of the company’s core assets, its Series A financing and its partnerships. Before Qpex, Jonathan served in various leadership roles at The Medicines Company, most recently as Vice President of Strategic Planning and Corporate Development, where he was instrumental in the divestiture of commercial-stage infectious disease assets to Melinta Therapeutics and the acquisition and subsequent integration of Rempex Pharmaceuticals. Jonathan has also held a variety of roles at SR One, Acceleron Pharma and Johnson & Johnson, spanning commercial planning and assessment, business development and finance. He holds an MBA from the Wharton School of the University of Pennsylvania and an AB in Biochemical Sciences from Harvard College.